The prestigious US National Institute of Health becomes a returning customer to AcouSort
In 2017, the US National Institute of Health (NIH) purchased the first AcouWash prototype for the cell wash process in a new monitoring method for cancer treatments that they were developing. AcouSort has now received an order from NIH for the new AcouWash 2 system.
Since 2017, the NIH researchers have conducted a study comparing AcouWash-based cell wash to a conventional centrifugation-based protocol. The results have been published in Scientific Reports, a journal from the Nature Portfolio, successfully validating the AcouWash for the intended application. The study is part of a larger project where NIH aims to develop a clinical process to monitor cancer treatment.
As a result of the success with replacing centrifugation with acoustic separation using the AcouWash, NIH has now decided to purchase the AcouWash 2 to use for further optimization of the new protocol. The new AcouWash 2 system offers significant benefits such as improved throughput and stability in performance.
“The success we have had collaborating with the American National Cancer Institute at NIH is extremely encouraging and marks an important step towards future integration of our technology in cancer treatment applications. It also validates our strategy to use benchtop systems as innovation platforms for customer evaluation. Finally, a second purchase from an acknowledgeable reference customer like NIH is about the best quality seal you can get in our business” says AcouSort’s CEO Torsten Freltoft.
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
About AcouSort
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank.